An Attempt to Develop a Radioactive Drug for Cancer Therapy by Professor J S Mitchell MD FRCP FRS (Department ofRadiotherapeutics, University of Cambridge, and Radiotherapeutic Centre, Addenbrooke's Hospital, Cambridge) This paper is a short survey of the work done so far, by a team in Cambridge, to try to develop a radioactive drug for use in the treatment of patients with cancer.
Tritium appears to be the most promising radioactive isotope for incorporation into a suitable carrier molecule. It emits only soft Pparticles, which have a range of about lI, in tissue corresponding to the mean energy. Accordingly, the biological effects are strictly localized and hazards in handling are easily reduced to a minimum. The radioactive half-life is 12-4 years but the values of the biological half-life are much less, e.g. thirteen days for some tumours and three to six days for many normal tissues including bone marrow. For uniformly distributed radioactive material, one millicurie of tritium per gram of tissue delivers a dose of 293 rads in twenty-four hours. The value of the relative biological effectiveness of the ,-rays of tritium in relation to 60Co y-rays is taken as 1-7. Tritium has become available in pure form in large amounts in recent years.
Most of our investigations have concerned tritiated derivatives of 2-methyl-1,4-naphthaquinol bis (disodium phosphate), Synkavit, our Compound 1 (see Fig 1) . This compound, which has been investigated since 1946 as a therapeutic radiosensitizer was found unexpectedly to concentrate to some extent selectively in the malignant cells of some human and animal tumours (Mitchell 1960 , Marrian, Marshall & Mitchell 1961 We came to investigate this development as a result of the clinical observation of focal sensations and sometimes pain in the region of the tumour, in addition to various nonspecific sensations, in some cases after intravenous injections of Synkavit. A number of studies of the distribution of Synkavit in tumours and some other tissues have been made using the methods of fluorescence with Wood's light (Mitchell 1948 (Mitchell , 1949 (Mitchell , 1953 (Mitchell , 1955 and of radioactive labelling with 14C, 82Br and 1311 (Marrian & Maxwell 1956a , b, Maxwell 1954 , 1955 . The radioactive halogen substituents proved labile under physiological conditions, as also had the 32P label studied by Neukomm et al. (1953) . Our investigations with Compound 1 labelled with 14C in the methylgroup confirmed the uptake and retention in some human tumours (Marrian & Maxwell 1956a , Horwitz et al. 1959 . Tritium became available and Compound 1 was prepared labelled with tritium in position 3 ofthe nucleus (Marrian 1957) . Although useful for tracer studies, the product had too low a specific activity for clinical use. Accordingly, since then, we have devoted our limited resources to the development and study of preparations of tritiated Compound 1 with high specific activity.
At the present time, we are investigating the tritritiated drug, 2-methyl-5, 6, 7-tritritio-1, 4naphthaquinol bis (disodium phosphate) (see Fig 1) . This compound with three firmly bound tritium atoms per molecule has a specific activity of 87-3 curies per millimol and 1 curie is contained in 4-88 mg of compound. It has been prepared as a result of a collaborative effort by the Department of Radiotherapeutics, University of Cambridge, the Radiochemical Centre, Amersham, and Roche Products, Welwyn Garden City (Andrews et al. 1962 ). The tritium is introduced by reductive dehalogenation of the corresponding tri-bromo-derivative, 2-methyl-5, 6, 7-tribromo-1, 4-naphthaquinol bis (disodium phosphate) using carrier-free tritium in the presence of a catalyst. The preparations used will be referred to as TRA 119, following the code of the catalogue of the Radiochemical Centre.
Earlier Stages A number of accounts of various aspects of the earlier laboratory and clinical investigations have been published (Horwitz et al. 1959 , Marrian, Marshall & Mitchell 1961 , Simon-Reuss 1961 Marrian, Marshall, Mitchell & Simon-Reuss 1961, Mitchell 1961 , 1963 , McKelvie 1962 , Chipperfield & Marrian 1962 . Information of great value from the point of view of the clinical applications in man was obtained in studies of the treatment of spontaneous malignant tumours and leukemias in dogs and cats (Silver et al. 1962) .
We started to investigate the use of tritiated preparations of Compound 1 in the treatment of patients with advanced malignant disease in February 1959. Throughout the whole of this investigation, the radioactive preparations have been administered by some form of intra-arterial injection whenever possible, otherwise by intravenous injection (Horwitz 1960 , Gregg 1958 . In the treatment of the first 27 patients, we used material tritiated by the Wilzbach exchange method but this contained incorporated tritium at only relatively low levels of specific activity, together with varying amounts of tritiated water. Then Marrian devised a method of tritiation which made it possible to obtain reliable preparations of the compound containing approximately one atom of tritium per molecule with the tritium firmly bound. This compound is 2-methyl-6-tritio-1,4-naphthaquinol bis (disodium phosphate), TRA 72 (Andrews et al. 1962) .
We have investigated TRA 72 in the treatment of 21 patients who were seriously ill with advanced, recurrent, radioresistant or refractory malignant disease. Temporary improvement assessed on the basis of observation of some form of definite objective improvement and/or striking relief of pain as indicated by a great reduction of the analgesics required, in particular discontinuance of the need for morphia, was observed in 5 of these 21 cases; there was probably some improvement attributable to the treatment in a further 4 cases. It appeared that under the conditions of this trial, definite though small palliative effects were observed; it seemed likely that these were associated with the relatively low levels of radiation dose de1iNered by the radioactive drug.
Extensive measurements of the specific activity of tritium in biopsy and autopsy specimens provided evidence for some degree of selective concentration of TRA 72 in certain human malignant tumours in relation to the bone marrow after both intra-arterial and intravenous administration. The specific activity of the specimens of tumour was almost invariably higher than that of specimens of bone marrow and of skeletal muscle, often by a factor of 3 and sometimes by a factor of 6 to 7. The values of the specific activity observed were such that it appeared that at least three atoms of tritium per molecule of Compound 1 are necessary to make it possible to deliver doses of radiation within the therapeutic range to those tumours with adequate uptake and a sufficiently high radiosensitivity. It was interesting to find with TRA 72 that when the tritium was firmly bound in the molecule, there was no clinical problem with toxic effects on the bone marrow.
Investigations ofthe Tritritiated Drug, TRA 119
In 1962 we carried out clinical and laboratory investigations of the therapeutic possibilities of the radioactive drug, TRA 119, containing tritium in very high specific activity.
There are still a number of problems to be solved in connexion with the preparation of TRA 119 for clinical use. Different batches vary in their specific activity. So far, each batch has been tested biologically before use (I) for acute toxicity after intravenous injection into rabbits, which are being kept for studies of possible late toxic effects, especially on the kidneys, and (2) on tissue cultures mainly of HeLa cells by Simon-Reuss to check sterility and to assess uptake of TRA 119 into the tumour cells under standard conditions by means of autoradiography (Simon-Reuss 1961).
On the clinical side, we have used TRA 119 between March 7, 1962, and December 17, 1962, in the treatment of 33 patients with various types of advanced and recurrent malignant diseases and allied conditions when conventional methods of treatment were not likely to help. In 15 of these, some form of intra-arterial injection was used; intravenous injection was used in the other 18 cases. In addition, 4 cases of carcinoma of the bronchus have been investigated by means of preoperative injections -3 intravenously and one into the pulmonary arterywith subtherapeutic doses of TRA 119.
It is, of course, too early to draw any general conclusions about the possible therapeutic value of TRA 119, and it is necessary to be extremely cautious. At the present time, it can be reported that there was useful relief of pain in 6 out of 9 cases in which pain was a serious problem. In one case, there appeared to be delayed retrogression of metastatic nodules of melanoma after three intraarterial injections of TRA 119; however, possibility of spontaneous retrogression must be raised. In a case of Hodgkin's disease, generalized pruritus was relieved after a single intravenous injection of a relatively small dose.
Evidence has been obtained which confirms the low toxicity of TRA 119 in patients with essentially normal bone marrow. There were 6 cases in which single intravenous doses of between 9-6 and 10-9 curies of TRX 119 were administered; only one of these, a case of carcinoma of the head of the pancreas with extensive metastases in bones, showed evidence of a serious fall in the level of blood platelets, with petechial hemorrhages. This example appears to have been the only serious toxic effect attributable to TRA 119 observed so far in this series of 33 cases.
The procedures for intra-arterial injection of TRA 119 and the methods used have been described elsewhere (Horwitz et al. 1959 , Gregg 1958 , Marrian, Marshall & Mitchell 1961 . In general, a preliminary arteriogram is carried out. Tolazoline has been used in many cases before the intra-arterial injection of TRA 119. Although the general policy has been to give a single intra-arterial injection of TRA 119, an attempt is now being made in some cases to repeat the intra-arterial injection after an interval of between ten days and four weeks. For both the intravenous and intra-arterial routes of administration, it is considered important to inject the TRA 119 as rapidly as possible in order to minimize its reaction with -SH compounds in the blood and to make certain that as high a proportion as possible reaches the tumour cells.
As with TRA 72, many measurements have been made of the specific activity of specimens of tumours and normal tissues obtained by biopsy, surgery and autopsy after the administration of TRA 119. For most of the specimens of tumour taken at thirty minutes after administration of the TRA 119, the specific activity had values between 25 and 300 ,c/g of wet tissue. In one case, of extensive recurrent squamous carcinoma ofthe left pinna, involving the side of the head and neck, following intra-arterial injection of 10 8 curies,the specific activity had the values 8,990 (± 2-7 %),uc/g for a biopsy from the anterior part of the lesion after thirty minutes and 1,815 (+3 8 %),uc/g for a biopsy from the posterior part of the lesion after three and a half hours. With certain assumptions, these macroscopic average values of the specific activity make it possible to calculate mean doses of radiation. These doses are of interest but by themselves do not give reliable information about the effective cell doses. The approximate proportion of the macroscopic specimen of tumour occupied by tumour cells can be determined by histological examination; however, this is still not the whole picture.
A detailed autoradiographic study has been carried out on many of the specimens of tumour for the cases treated by TRA 119. The findings have been considered in relation to the measurements of the specific activity of the macroscopic specimens and the results have been discussed in selected cases with special reference to dosimetry (Mitchell et al. 1963) . Approximate counts of labelled cells and grain counts have been made on tumour cells and on normal cells of the adjacent stroma.
Conclusions
The results of the autoradiographic and related studies provide evidence for some degree of selective concentration of TRA 119 in the tumour cells in relation to normal cells in some cases of certain types of malignant disease. This is the case for both intravenous and intra-arterial administration.
The estimated doses of radiation delivered by the tritium are consistent with the clinical findings that after intravenous injection of TRA 119, palliative effects may be produced in cases of highly radiosensitive conditions, such as testicular seminoma and Hodgkin's disease, and also in certain cases of slowly progressive recurrent adenocarcinoma of the gastro-intestinal tract.
Intra-arterial administration of TRA 119 appears to be necessary to attain therapeutic levels of the dose of radiation in the attempted treatment of patients with relatively localized but otherwise untreatable malignant disease of the histological types squamous carcinoma, melanoma and adenocarcinoma. The present evidence together with that of earlier studies with TRA 72 suggests the desirability of further investigation of the possible value of intra-arterial therapy with TRA 119 in selected otherwise untreatable cases of squamous carcinoma of the head and neck and also of the parametrium in carcinoma of the uterine cervix, stage III, malignant tumours of the limbs, including melanoma and tumours of bone and adenocarcinoma of the gastro-intestinal tract.
It is emphasized that much further investigation of the dose and time factors is required, particularly in connexion with the need for repetition of intra-arterial injections at intervals comparable with the biological mean life of the tritium in the tumour.
The possibility of biochemical differences between some malignant and some normal cells must be envisaged in relation to the actions of Compound 1, Synkavit and menadione, 2-methyl-1, 4-naphthaquinone, the parent quinone which almost certainly is the effective form of the molecule within the cells. The selective uptake of TRA 119 into certain malignant cells is of biochemical interest, particularly in relation to the recent findings of low concentrations of co-enzyme Q (ubiquinone) in some tumours, and of the greater increase in the activity of certain oxidative enzymes produced by the addition of co-enzyme Qlo or menadione in tumour than in homologous normal tissue , Osterberg & Wattenberg 1961 
